PPP1R12C

Across TCGA pan-cancer cohorts, PPP1R12C Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PPP1R12C data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PPP1R12C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PPP1R12C expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

LIHC and COAD are the cancer types where PPP1R12C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.186	0.719	.001	21	view →
COAD	DFS	Median	II,III,IV	1.000	0.473	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PPP1R12C–LIHC (OS)

Open the LIHC breakdown →